KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbbVie (ABBV) Exchange Rate Effect (2016 - 2025)

Historic Exchange Rate Effect for AbbVie (ABBV) over the last 13 years, with Q3 2025 value amounting to -$8.0 million.

  • AbbVie's Exchange Rate Effect fell 20000.0% to -$8.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$15.0 million, marking a year-over-year decrease of 47500.0%. This contributed to the annual value of -$65.0 million for FY2024, which is 140000.0% down from last year.
  • Per AbbVie's latest filing, its Exchange Rate Effect stood at -$8.0 million for Q3 2025, which was down 20000.0% from $30.0 million recorded in Q2 2025.
  • Over the past 5 years, AbbVie's Exchange Rate Effect peaked at $30.0 million during Q2 2025, and registered a low of -$59.0 million during Q3 2022.
  • Its 5-year average for Exchange Rate Effect is -$9.9 million, with a median of -$9.0 million in 2024.
  • Its Exchange Rate Effect has fluctuated over the past 5 years, first plummeted by 78333.33% in 2021, then surged by 43333.33% in 2025.
  • Quarter analysis of 5 years shows AbbVie's Exchange Rate Effect stood at -$28.0 million in 2021, then soared by 182.14% to $23.0 million in 2022, then changed by 0.0% to $23.0 million in 2023, then tumbled by 300.0% to -$46.0 million in 2024, then skyrocketed by 82.61% to -$8.0 million in 2025.
  • Its Exchange Rate Effect stands at -$8.0 million for Q3 2025, versus $30.0 million for Q2 2025 and $9.0 million for Q1 2025.